Third-Party Payers Have No Class: Zyprexa Ruling Cites Non-Uniform Pricing In Tossing Out Group Challenge
Executive Summary
Third-party payers had hoped to obtain billions in damages in a suit claiming Eli Lilly & Co. misrepresented the side effects and safety of its antipsychotic Zyprexa (olanzapine). But an appeals court reversed their class certification and also found that they could not proceed with their main theory of damages as individual plaintiffs.
You may also be interested in...
Lilly Will Not Settle Zyprexa Overpricing Suit; Judge Finds Evidence Of Fraud
Lilly intends to fight rather than settle a suit by third party payers alleging the company overpriced its antipsychotic drugZyprexa (olanzapine)
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.